Ashkenazi Jewish Genetic Diseases: A Comprehensive Guide to Testing

Why Are Certain Genetic Diseases More Common in Ashkenazi Jews?

The elevated rates of genetic disease in the Ashkenazi Jewish community are not a coincidence; they are the direct result of population history. Scientists call the explanation the founder effect, and it is one of the best-studied examples of this phenomenon in any human population.

Research published in PNAS and supported by multiple population genetics studies has found that the Ashkenazi Jewish population experienced at least two severe population bottlenecks (dramatic reductions in population size) that sharply narrowed genetic diversity.² The first occurred around 70 CE at the beginning of the Jewish Diaspora. A second, more severe bottleneck occurred between approximately 1100 and 1400 CE, during a period of crusades, persecution, and the Black Death. Genetic research suggests that the modern Ashkenazi Jewish population descends from as few as 300–500 effective ancestors from this medieval period.

When a population shrinks dramatically and then expands rapidly, genetic mutations that happened to exist in that small founding group become disproportionately common in all descendants.² This is why the same handful of disease-causing mutations appear in the vast majority of Ashkenazi Jewish carriers today.¹

What Are the Most Common Ashkenazi Jewish Genetic Diseases?

The following conditions have significantly elevated carrier rates in individuals of Ashkenazi Jewish descent.³ All are autosomal recessive unless otherwise noted, meaning a child must inherit two copies of the mutated gene (one from each parent) to be affected. A child who inherits only one copy is a carrier and is typically healthy.⁴

1. Gaucher Disease — Carrier Rate: 1 in 10 to 1 in 15

Gaucher disease is the most common Ashkenazi Jewish genetic disorder.³ It results from a deficiency of the enzyme glucocerebrosidase, which causes a buildup of fatty substances in organs and tissues, particularly the liver, spleen, and bone marrow. Type 1 Gaucher disease (the most common form in Ashkenazi Jews) is treatable with enzyme replacement therapy, and many individuals with Type 1 live full, healthy lives with proper management. Types 2 and 3 are more severe neurological forms. The carrier rate of approximately 1 in 10 Ashkenazi Jews makes it the highest-frequency Ashkenazi Jewish mutation of any condition.

2. Cystic Fibrosis — Carrier Rate: 1 in 24 to 1 in 27

Cystic fibrosis (CF) is a progressive disease caused by a defect in the CFTR gene, resulting in the production of abnormally thick, sticky mucus that obstructs the lungs and digestive system.⁵ CF causes chronic respiratory infections, poor growth, and reduced life expectancy. While CF affects individuals of all ancestries (approximately 1 in 25 white Americans of European descent is a carrier) the carrier rate is similarly elevated among Ashkenazi Jews. Advances in CFTR modulator therapies have significantly extended life expectancy in recent decades, but CF remains a serious lifelong condition. 

3. Tay-Sachs Disease — Carrier Rate: 1 in 30

Tay-Sachs is perhaps the best-known Ashkenazi Jewish genetic disease. It is caused by a deficiency of the enzyme hexosaminidase A (Hex-A), which leads to a progressive and fatal destruction of nerve cells in the brain and spinal cord.⁶ Infants with Tay-Sachs appear normal at birth but begin to lose developmental milestones at 3 to 6 months of age. The disease progresses relentlessly, and most children with classical infantile Tay-Sachs do not survive past age 4 to 6.⁶ There is currently no cure or effective treatment. About 1 in 30 Ashkenazi Jews carries the Tay-Sachs gene. Carrier screening programs launched in the 1970s dramatically reduced Tay-Sachs incidence in the Jewish community — it is one of the great success stories of preventive genetics.⁶

4. Familial Dysautonomia (Riley-Day Syndrome) — Carrier Rate: 1 in 30

Familial dysautonomia (FD) is a disorder of the autonomic and sensory nervous systems. Affected individuals are unable to properly regulate blood pressure, body temperature, digestion, and swallowing, and they do not feel pain normally. FD causes recurrent pneumonias, vomiting crises, unstable blood pressure, and progressive disability. It occurs almost exclusively in Ashkenazi Jews — approximately 99% of all FD cases worldwide are in individuals of Ashkenazi descent. Life expectancy has improved with supportive care, but there is no cure. The carrier rate is approximately 1 in 30 among Ashkenazi Jews.³

5. Canavan Disease — Carrier Rate: 1 in 40

Canavan disease is a fatal neurological disorder caused by a deficiency of the enzyme aspartoacylase, which leads to progressive degeneration of myelin, the protective coating of nerve fibers in the brain. Affected children typically do not develop normally past 3 to 6 months, often cannot sit up, roll over, or speak, and typically die in childhood. There is no cure. Research into gene therapy is ongoing. The carrier rate among Ashkenazi Jews is approximately 1 in 40.³

6. Niemann-Pick Disease Type A — Carrier Rate: 1 in 90

Niemann-Pick disease type A is a severe lysosomal storage disorder affecting infants. It causes progressive neurological deterioration, enlargement of the liver and spleen, and feeding difficulties. Most affected children do not survive past 4 years of age, and there is currently no treatment. The carrier rate in the Ashkenazi Jewish population is approximately 1 in 90.³

7. Bloom Syndrome — Carrier Rate: 1 in 100

Bloom syndrome is a chromosomal breakage disorder characterized by short stature, sun sensitivity, immune deficiency, and a dramatically increased susceptibility to cancer. Most individuals with Bloom syndrome develop cancer before age 30, and their average life expectancy is significantly reduced. The carrier rate in Ashkenazi Jews is approximately 1 in 100. There is no cure, but early cancer surveillance can be lifesaving.³

8. Fanconi Anemia Group C — Carrier Rate: 1 in 89

Fanconi anemia is an inherited bone marrow failure syndrome. Affected individuals develop progressive anemia, are at high risk for leukemia and solid tumors, and may also have physical abnormalities, including limb differences and growth deficiency. Bone marrow transplantation can treat the blood disorder, but it does not reduce cancer risk. The carrier rate in Ashkenazi Jews for the Group C subtype is approximately 1 in 89.³

9. Mucolipidosis Type IV (ML4) — Carrier Rate: 1 in 122

Mucolipidosis type IV is a lysosomal storage disorder that typically appears in the first year of life. It causes severe motor delays, intellectual disability, and progressive vision loss due to retinal degeneration, often leading to blindness. Most affected individuals reach a developmental level equivalent to a 1 to 2-year-old. There is no treatment or cure.³

10. Glycogen Storage Disease Type 1a (GSD-1a) — Carrier Rate: 1 in 71

GSD-1a causes the body to be unable to properly regulate blood sugar, resulting in dangerously low blood glucose (hypoglycemia), an enlarged liver, slow growth, and, in severe cases, kidney disease and liver tumors. Treatment requires strict dietary management and continuous glucose feeding. With proper treatment, affected individuals can live into adulthood, though vigilant management is essential.³

11. Maple Syrup Urine Disease Type 1B (MSUD) — Carrier Rate: 1 in 81

MSUD is a metabolic disorder in which the body cannot break down certain amino acids. Without treatment, it leads to neurological damage, coma, and death. The condition gets its name from the distinctive maple syrup odor of the urine of affected infants. Treatment requires a lifelong, tightly controlled special diet. The carrier rate among Ashkenazi Jews is approximately 1 in 81.³

12. Spinal Muscular Atrophy (SMA) — Carrier Rate: 1 in 40 to 1 in 60

Spinal muscular atrophy is a severe neuromuscular disease caused by mutations in the SMN1 gene. It leads to progressive muscle weakness and, in the most severe form (Type 1), respiratory failure and death typically before age 2. Carrier rates are elevated in Ashkenazi Jews compared to the general population. Importantly, new gene therapies and medications have revolutionized outcomes for affected children when diagnosed early, making newborn screening and carrier testing critically important.⁵

13. Familial Hyperinsulinism — Carrier Rate: 1 in 52 (ABCC8 mutations)

Familial hyperinsulinism causes the pancreas to produce too much insulin, resulting in persistent and dangerous low blood sugar (hypoglycemia) in newborns and infants. Without prompt diagnosis and treatment, it can cause permanent brain damage. Elevated rates of ABCC8 gene mutations causing this condition have been documented in the Ashkenazi Jewish population. Treatment options include medication and, in some cases, partial or near-total pancreatectomy.³

14. Joubert Syndrome Type 2 — Carrier Rate: 1 in 92

Joubert syndrome type 2 (TMEM216 gene) is a rare brain malformation disorder causing a characteristic abnormality of the cerebellum and brainstem (known as the 'molar tooth sign' on MRI). Affected individuals experience breathing abnormalities at birth, abnormal eye movements, hypotonia (reduced muscle tone), intellectual disability, and often kidney disease. There is no cure; management is supportive. Ashkenazi Jews carry elevated rates of the founder mutation in TMEM216.³

BRCA1 and BRCA2: The Ashkenazi Jewish Cancer Connection

In addition to autosomal recessive conditions, individuals of Ashkenazi Jewish descent face a significantly elevated risk for hereditary cancers due to founder mutations in the BRCA1 and BRCA2 genes. Unlike the conditions above, BRCA mutations follow an autosomal dominant inheritance pattern, meaning only one mutated copy is needed to elevate cancer risk, and each child of a carrier has a 50% chance of inheriting the mutation.

Three specific BRCA founder mutations — BRCA1 185delAG, BRCA1 5382insC, and BRCA2 6174delT account for the vast majority of hereditary breast and ovarian cancer risk in Ashkenazi Jews.⁷ Approximately 1 in 40 individuals of Ashkenazi Jewish descent carries one of these three mutations, compared to approximately 1 in 400 in the general population — a tenfold difference.⁸

Carriers face lifetime breast cancer risks of up to 72% (BRCA1) or 69% (BRCA2) and ovarian cancer risks of up to 44% (BRCA1).⁹ Read more in our detailed guide: BRCA Gene Inheritance Explained: Making Testing Decisions for Your Family.

BRCA testing is offered through jscreen's hereditary cancer screening test, which covers 63 genes, including BRCA1 and BRCA2. According to NCCN guidelines, all individuals of Ashkenazi Jewish descent should be offered BRCA testing regardless of personal or family cancer history.

Who Should Get Ashkenazi Jewish Genetic Testing?

According to guidelines from both ACMG (American College of Medical Genetics and Genomics) and ACOG (American College of Obstetricians and Gynecologists), Ashkenazi Jewish genetic carrier screening should be offered to any individual of Ashkenazi Jewish descent who is pregnant or considering pregnancy.^{10, 11}

You should consider genetic testing if:

• You have at least one parent, grandparent, or great-grandparent of Ashkenazi Jewish descent. Even partial ancestry warrants consideration.¹⁰
• Your partner is of Ashkenazi Jewish descent, even if you are not. If the Jewish partner is a carrier, the non-Jewish partner should be tested for that specific condition.¹¹
• You are an interfaith couple — expanded pan-ethnic carrier screening panels cover both Ashkenazi-specific conditions and conditions common across all ancestries.⁴
• You are using donor eggs or sperm — donor screening alone may not cover every condition on a comprehensive panel.
• You have a family history of any known Jewish genetic disorder, regardless of your percentage of Jewish ancestry.
• You have already had one child with a genetic disorder and are planning future pregnancies.

Do I need to know my exact percentage of Jewish ancestry?

No. Even one Jewish grandparent is considered a sufficient reason to pursue Ashkenazi Jewish genetic carrier screening.⁴ Because the founder mutations in this population are highly specific and well-characterized, testing is informative even for individuals with partial Ashkenazi ancestry. If you are uncertain about your ancestry, an at-home test remains a reasonable step, and jscreen's Expanded Carrier Screening Panel covers conditions common across all ethnic backgrounds, not only those specific to Ashkenazi Jews. 

‍

How Ashkenazi Jewish Genetic Testing Works: Step by Step

Ashkenazi Jewish genetic carrier testing has never been more accessible. Through jscreen's at-home reproductive carrier screen, the process is simple, private, and clinically supported from start to finish:

1. Order your kit online at jscreen.org. Complete a brief health questionnaire during registration — this helps ensure the most appropriate testing for your situation.
2. Receive your kit in the mail within 7–10 business days. No doctor's visit or referral is required to order.
3. Collect your saliva sample at home — the process is painless and takes only a few minutes. 
4. Mail your sample to the certified laboratory using the included pre-paid envelope. 
5. Receive your results within approximately 2–4 weeks, reviewed with a certified genetic counselor via a telehealth appointment — included with every jscreen test at no additional charge.

Understanding Your Ashkenazi Jewish Carrier Screening Results

Negative Result

A negative result means no mutations were detected in the genes on the panel. This significantly reduces, but does not entirely eliminate, your risk of being a carrier, because no panel detects 100% of all possible variants. For most Ashkenazi Jewish conditions, panel detection rates are 95% or higher for the specific founder mutations, making a negative result highly reassuring.³

Positive (Carrier) Result

A positive carrier result means you carry one mutation in a gene associated with a particular condition. Carriers are almost always healthy — carrying one copy of a recessive mutation does not cause the condition.The critical implication is for your reproductive planning: if both you and your partner are carriers for the same condition, each pregnancy carries a 25% chance of an affected child. Your genetic counselor will explain your specific result and discuss all available options. Learn more about what to do if both partners are carriers.⁴

Variant of Uncertain Significance (VUS)

Occasionally, a test identifies a genetic change whose significance is not yet fully understood. A VUS is neither a positive nor a negative result, and medical decisions should not be based on a VUS alone.⁵  As research advances, VUS results are frequently reclassified. Your genetic counselor will monitor for any reclassification and advise you accordingly.

‍

Reproductive Options When Both Partners Are Carriers

Finding out that both partners carry the same mutation is a challenging moment — but it is not the end of the conversation. It is the beginning of an informed one. As noted by UCSF Health's genetic counseling program, several evidence-based options are available^12:

• Preimplantation genetic testing (PGT) with IVF — embryos are tested before transfer, allowing only unaffected embryos to be implanted. This is the most proactive option for couples who wish to have a biological child without the condition.¹⁵
• Prenatal diagnostic testing — chorionic villus sampling (CVS) at 10–13 weeks or amniocentesis at 15–20 weeks can determine whether a pregnancy is affected.¹³
• Donor eggs or sperm from a screened non-carrier donor.
• Adoption or other paths to parenthood — many families choose this route.
• Natural conception with full awareness of the statistical risk and preparation for potential medical needs.

When one parent is a carrier and the other is not, each child has a 50% chance of being a carrier like the carrier parent, and no chance of having the disease.¹ In that scenario, prenatal diagnostic testing is not typically recommended.

Frequently Asked Questions About Ashkenazi Jewish Genetic Testing

Does Jewish genetic testing require a doctor's referral?

No. Through jscreen, you can order an at-home carrier screening kit directly online without a physician referral. Physician oversight and genetic counseling are built into jscreen's process — you are never without clinical support, but you do not need to visit a doctor to get started.

Is Ashkenazi Jewish carrier screening covered by insurance?

Many major insurance plans cover expanded carrier screening for individuals of Ashkenazi Jewish descent who meet clinical criteria.¹⁰ jscreen bills insurance on your behalf, and data shows that over 90% of jscreen customers who pursue hereditary cancer testing pay nothing out-of-pocket. For those without insurance or with high deductibles, self-pay options are available, and financial assistance programs exist for those who qualify.

What if only one of my grandparents was Ashkenazi Jewish?

Carrier screening is still recommended. Even partial Ashkenazi ancestry places you at elevated risk relative to the general population, and the highly specific founder mutations in Ashkenazi-associated conditions are reliably detected by modern panels.¹⁰ jscreen's expanded carrier screen also covers conditions found across all ancestries, making it informative regardless of your background.

My parents were already tested for Tay-Sachs years ago. Do I still need testing?

Possibly yes — for two important reasons. First, older Tay-Sachs testing used enzyme assays that have been largely replaced by more sensitive DNA-based testing.⁶ Second, even if your parents tested negative for Tay-Sachs specifically, modern expanded panels test for many additional conditions — conditions your parents may never have been screened for, including Familial Dysautonomia, Canavan disease, Gaucher disease, Bloom syndrome, and many more. A current comprehensive panel is the most complete and actionable approach.

What is the difference between carrier screening and diagnostic testing?

Carrier screening is done in healthy individuals to determine whether they carry one copy of a gene mutation associated with a recessive condition. It does not diagnose a disease in the person being tested; it assesses their risk of having an affected child if their partner is also a carrier.¹³  Diagnostic testing, by contrast, is done when a disease is suspected in an individual who shows symptoms. Carrier screening is the appropriate first step for people planning a family.

Can men be carriers for these conditions?

Yes. For autosomal recessive conditions, men and women are equally likely to be carriers, and carrier status affects the risk to future children equally, regardless of which parent carries the mutation. Both partners should ideally be tested before or during pregnancy.

What is expanded carrier screening, and how does it differ from Ashkenazi-only panels?

Traditional Ashkenazi Jewish genetic panels tested for a set list of conditions with elevated rates specifically in the Ashkenazi population — typically 10–20 conditions. Expanded carrier screening (ECS) panels test for hundreds of conditions across all ethnic backgrounds.¹³  ACMG guidelines now recommend offering ECS to all individuals considering pregnancy, regardless of ancestry, because many serious recessive conditions affect individuals of all backgrounds.⁴ jscreen's reproductive carrier screen is an expanded panel that includes Ashkenazi-specific conditions as well as conditions found across all ancestries.

Ready to Get Tested? Order your at-home carrier screening kit today at jscreen.org. No doctor's referral needed. Genetic counseling included. Financial assistance available.

Related Reading:

• BRCA Gene Inheritance Explained: Making Testing Decisions for Your Family
• What to Do If Both Partners Are Carriers
• Reproductive Carrier Screen: What's Included and Why It Matters
• Hereditary Cancer Screening: BRCA1, BRCA2, and Beyond
• Genetic Counseling: What to Expect from Your Appointment
• Sephardic and Mizrahi Jewish Genetic Conditions: What You Need to Know

‍

‍

‍

References

1. Jewish Genetic Disease Consortium. Carrier screening overview. Jewish Genetic Disease Consortium website. Published 2023. Accessed April 24, 2026. https://www.jewishgeneticdiseases.org/genetics-and-carrier-screening/
2. Kopelman NM, Stone L, Wang C, et al. Distinguishing between founder and host population mtDNA lineages in the Ashkenazi population. Gene. 2025;890:148000. doi:10.1016/j.gene.2025.148000
3. ARUP Consult. Ashkenazi Jewish genetic diseases. ARUP Laboratories website. Updated October 2024. Accessed April 24, 2026. https://arupconsult.com/content/ashkenazi-jewish-genetic-diseases
4. Sagaser KG, Malinowski J, Westerfield L, et al. Expanded carrier screening for reproductive risk assessment: an evidence-based practice guideline from the National Society of Genetic Counselors. J Genet Couns. 2023;32(3):540-557. doi:10.1002/jgc4.1676
5. Goldberg JD, Pierson S, Johansen Taber K. Expanded carrier screening: what conditions should we screen for? Prenat Diagn. 2023;43(4):496-505. doi:10.1002/pd.6306
6. Bhutani VK, Johnson-Hamerman L, Wong RJ. Tay-Sachs disease. In: StatPearls [Internet]. StatPearls Publishing; 2024. Updated October 6, 2024. Accessed April 24, 2026. https://www.ncbi.nlm.nih.gov/books/NBK564432/
7. Brezis M, Rottenberg Y, Tanos V, et al. Carrier screening program for BRCA1/BRCA2 pathogenic variants among Ashkenazi Jewish women in Israel: an observational study. Genet Med Open. 2023;1(1):100808. doi:10.1016/j.gimo.2023.100808
8. Garber J. What's the connection between BRCA and Ashkenazi Jewish ancestry? Dana-Farber Cancer Institute website. Published June 26, 2023. Accessed April 24, 2026. https://blog.dana-farber.org/insight/2023/06/whats-the-connection-between-brca-and-ashkenazi-jewish-ancestry/
9. National Cancer Institute. BRCA gene changes: cancer risk and genetic testing. National Institutes of Health website. Updated November 25, 2024. Accessed April 24, 2026. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet
10. American College of Obstetricians and Gynecologists. Committee Opinion No. 690: Carrier screening in the age of genomic medicine. Obstet Gynecol. 2017;129(3):e35-e40. Reaffirmed 2023.
11. American College of Obstetricians and Gynecologists. Committee Opinion No. 691: Carrier screening for genetic conditions. Obstet Gynecol. 2017;129(3):e41-e55. Reaffirmed 2023.
12. Society for Assisted Reproductive Technology. Preimplantation genetic testing. SART website. Published 2024. Accessed April 24, 2026. https://www.sart.org
13. Santoli F, Esteves SC, Yarali H, et al. An overview of current prenatal genetic screening and diagnosis guidelines. Pregnancy. 2025

‍

‍